20.95
price down icon1.37%   -0.29
after-market アフターアワーズ: 20.95
loading
前日終値:
$21.24
開ける:
$21.38
24時間の取引高:
916.96K
Relative Volume:
0.46
時価総額:
$3.73B
収益:
$890.53M
当期純損益:
$30.57M
株価収益率:
116.39
EPS:
0.18
ネットキャッシュフロー:
$80.53M
1週間 パフォーマンス:
-5.67%
1か月 パフォーマンス:
-4.69%
6か月 パフォーマンス:
+13.80%
1年 パフォーマンス:
+34.38%
1日の値動き範囲:
Value
$20.84
$21.41
1週間の範囲:
Value
$20.84
$22.56
52週間の値動き範囲:
Value
$13.40
$25.23

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
名前
Acadia Pharmaceuticals Inc
Name
セクター
Healthcare (1160)
Name
電話
858-558-2871
Name
住所
12830 EL CAMINO REAL, SAN DIEGO
Name
職員
654
Name
Twitter
@acadiapharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
ACAD's Discussions on Twitter

ACAD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
20.95 3.73B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-21 アップグレード Deutsche Bank Hold → Buy
2025-02-11 開始されました Deutsche Bank Hold
2025-01-03 ダウングレード Guggenheim Buy → Neutral
2024-10-10 再開されました Raymond James Mkt Perform
2024-08-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-06-27 開始されました BMO Capital Markets Outperform
2024-03-12 ダウングレード Mizuho Buy → Neutral
2024-03-12 繰り返されました Needham Buy
2024-01-30 開始されました Robert W. Baird Outperform
2024-01-24 アップグレード Needham Hold → Buy
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-12-14 ダウングレード Deutsche Bank Buy → Hold
2023-12-13 開始されました Citigroup Buy
2023-12-12 開始されました Deutsche Bank Buy
2023-11-06 アップグレード Mizuho Neutral → Buy
2023-10-17 開始されました UBS Buy
2023-10-10 アップグレード JP Morgan Neutral → Overweight
2023-01-03 アップグレード Guggenheim Neutral → Buy
2022-11-04 ダウングレード Goldman Neutral → Sell
2022-11-01 開始されました Loop Capital Hold
2022-08-08 ダウングレード Citigroup Buy → Neutral
2022-08-05 ダウングレード Citigroup Buy → Neutral
2022-06-21 ダウングレード Jefferies Buy → Underperform
2022-06-16 アップグレード Jefferies Hold → Buy
2022-03-16 アップグレード Canaccord Genuity Hold → Buy
2022-02-09 アップグレード H.C. Wainwright Neutral → Buy
2022-01-05 アップグレード Citigroup Neutral → Buy
2021-12-21 ダウングレード Guggenheim Buy → Neutral
2021-11-01 アップグレード Guggenheim Neutral → Buy
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-06-10 開始されました Berenberg Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-06 ダウングレード Canaccord Genuity Buy → Hold
2021-04-06 ダウングレード Goldman Buy → Neutral
2021-04-06 ダウングレード Jefferies Buy → Hold
2021-04-06 ダウングレード Mizuho Buy → Neutral
2021-04-05 ダウングレード Raymond James Outperform → Mkt Perform
2021-03-10 ダウングレード BofA Securities Buy → Neutral
2021-03-09 ダウングレード Citigroup Buy → Neutral
2021-03-09 ダウングレード Guggenheim Buy → Neutral
2021-03-09 繰り返されました H.C. Wainwright Buy
2021-03-09 ダウングレード Raymond James Strong Buy → Outperform
2021-03-09 ダウングレード Stifel Buy → Hold
2020-12-16 開始されました Mizuho Buy
2020-11-16 アップグレード Raymond James Outperform → Strong Buy
2020-08-25 開始されました Raymond James Outperform
2020-08-20 開始されました Morgan Stanley Overweight
2020-07-07 アップグレード Stifel Hold → Buy
2020-04-16 開始されました Jefferies Buy
2020-03-31 アップグレード Goldman Neutral → Buy
2020-03-06 開始されました Citigroup Buy
2019-12-16 開始されました Guggenheim Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-01 開始されました RBC Capital Mkts Outperform
2019-09-13 アップグレード SVB Leerink Mkt Perform → Outperform
2019-09-10 アップグレード Canaccord Genuity Hold → Buy
2019-07-23 繰り返されました Needham Buy
2018-12-10 開始されました Canaccord Genuity Hold
2018-09-21 アップグレード Piper Jaffray Neutral → Overweight
2018-08-09 繰り返されました Stifel Hold
2018-08-07 開始されました Stifel Hold
2018-08-06 ダウングレード Piper Jaffray Overweight → Neutral
2017-10-06 再開されました Goldman Neutral
すべてを表示

Acadia Pharmaceuticals Inc (ACAD) 最新ニュース

pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

Acadia wins patent appeal for key drug composition - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Acadia gets court approval related to Nuplazid patent - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review

Jun 10, 2025
pulisher
Jun 10, 2025

ACAD Patent Victory Secures Nuplazid Exclusivity Till 2030 | ACA - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case - BusinessLine

Jun 10, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ. - Law360

Jun 09, 2025
pulisher
Jun 09, 2025

Federal Court Upholds Acadia Pharmaceuticals (ACAD) Patent Victo - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Victory - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : ACADIA Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Drug - U.S. News & World Report

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia gets court approval related to Nuplazid patent (ACAD) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Yahoo

Jun 09, 2025
pulisher
Jun 06, 2025

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $3 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from J - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from JP Morgan | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $30 Following Patent Win | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Insider Sell: Laura Brege Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Secu - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Securities | ACAD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 | ACAD Stock News - GuruFocus

Jun 05, 2025

Acadia Pharmaceuticals Inc (ACAD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
大文字化:     |  ボリューム (24 時間):